Dr. Ornstein on antibody-drug conjugates for immunotherapy-refractory urothelial carcinoma

“The management of patients with advanced urothelial carcinoma whose cancer has progressed on immunotherapy presents a unique challenge,” says Moshe Ornstein, MD.

Moshe Ornstein, MD, MA, Department of Hematology and Medical Oncology, Cleveland Clinic, discusses the emergence of antibody-drug conjugates as a treatment option for patients with immune checkpoint inhibitor–refractory advanced urothelial carcinoma.